Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

44%

4 trials in Phase 3/4

Results Transparency

0 of 9 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

5(55.6%)

Phase 4

4(44.4%)

9Total

N/A(5)

Phase 4(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT02693392Not ApplicableCompleted

Clinical Evaluation of Fenugreek Seed Extract, a Nutraceutical in Patients With Type- 2 Diabetes

Role: collaborator

NCT03066089Phase 4Completed

Clinical Evaluation of Fenfuro (Fenugreek Seed Extract) in Type-2 Diabetic Subjects: an add-on Study

Role: lead

NCT02703064Not ApplicableCompleted

Furocyst - Poly Cystic Ovary Syndrome Study

Role: lead

NCT02702882Not ApplicableCompleted

The Efficacy Study of FUROSAP: A Testosterone Booster Supplement In Humans.

Role: lead

NCT02703025Not ApplicableCompleted

Evaluation of GCB-70 in Overweight Subjects

Role: lead

NCT02702947Phase 4Completed

Efficacy of Prunus Domestica Extract in BPH

Role: lead

NCT02748005Not ApplicableCompleted

Evaluation of Furosap in Human Volunteers

Role: lead

NCT02789488Phase 4Completed

Clinical Evaluation of Furocyst in Patients With Poly Cystic Ovary Syndrome

Role: lead

NCT02700477Phase 4Completed

Evaluation of Fenugreek Seed Extract In Type- 2 Diabetes: An Add-On Study

Role: lead

All 9 trials loaded